What’s New in Lupus: 3 Potential Targets for Therapy

May 22, 2018
Mark L. Fuerst

Researchers have set their sights on macrophage activation syndrome, pathways identified in renal cells, and mechanistic target of rapamycin.

References1. Borgia RE, Gerstein M, Levy DM, et al. Features, treatment, and outcomes of macrophage activation syndrome in childhood‐onset systemic lupus erythematosus. Arthritis Rheumatol. 2018;70:616-624. doi: 10.1002/art.40417.2. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Accelerating Medicines Partnership (AMP). Accessed May 22, 2018.3. Kato H, Perl A. Blockade of Treg cell differentiation and function by the interleukin-21-mechanistic target of rapamycin axis via suppression of autophagy in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2018;70:427-438. doi: 10.1002/art.40380.

Related Content:

News